Prescient Therapeutics June 2015 Appendix 4C

Melbourne, 30th July 2015, ASX Announcement

Prescient Therapeutics Limited (“Prescient or the Company”) provides a the following Appendix 4C in relation to the quarter ended 30 June 2015.

During the quarter, Prescient secured agreement from the United States Food and Drug Administration (FDA) to transfer sponsorship to Prescient of the Investigational New Drug (IND) – PTX-200, the company’s lead product.

Prescient also announced highly encouraging data from a pre-clinical trial of its novel compound PTX-100 in multiple myeloma at a prestigious U.S. oncology conference. Moffitt Cancer Care scientists examined the effect of Prescient’s small molecule compound PTX-100, a GGT-1 inhibitor that targets one of the RAS signaling pathways, in a mouse model highly relevant to multiple myeloma. They found the compound significantly decreased the percentage of multiple myeloma tumors within the bone and also offered a substantial improvement on mouse median several times.

During the quarter, Prescient appointed an internationally regarded pharmaceutical executive as Chief Medical Officer, Dr Terrance Chew, who will oversee clinical development and regulatory strategy for Prescient’s two novel oncology candidates now in mid-stage clinical trials at leading US cancer centres.

To read the full announcement, please click here.